Market Intelligence, Clinical Progress, and High-Purity Reagents for Brain Delivery, Oncology, and CNS Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD71/TFRC drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD71/TFRC ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CD71 Products |
| Gene Delivery | CD71 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Ideal for internalization and flow cytometry assays. | View CD71 Products |
| Benchmark Ab | Anti-CD71/TFRC Reference Antibody (Recombinant). Sequence-matched positive control for binding and blocking assays. | View CD71 Products |
| Validator | CD71/TFRC siRNA Set. Predesigned for knockdown verification and assay specificity controls. | View CD71 Products |
| Related Target A | TREM2. Neuroinflammation target commonly fused with CD71 BBB shuttles. | View TREM2 Products |
| Related Target B | BACE1. Alzheimer's target for bispecific BBB delivery validation. | View BACE1 Products |
| Related Target C | TFR2. Paralog selectivity assays; critical off-target counter-screen for TFRC programs. | View TFR2 Products |
| Related Target D | SLC40A1 (Ferroportin). Iron-export pathway node; combination and ferroptosis synergy screening. | View SLC40A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Precise Affinity Tuning for BBB Transcytosis | High Purity (>95%) HEK293 Expressed ECD-Fc for accurate SPR/BLI kinetics measurement. |
| pH-Dependent Transcytosis (pH 7.4 binding, pH 5.5 release) | Native glycosylation supports conformational folding; enables endosomal release assay. |
| Cross-species Translation (Cyno/Mouse) | Human, Cynomolgus, and Mouse ortholog proteins strictly sequence verified (>95% purity, endotoxin controlled). |
| Lack of Controls | Clinical Benchmark Antibodies included; predesigned siRNA for specificity checks. |
| False Positives in Endocytosis Assays | Validated siRNA included for knockdown verification. |
| TFR2 / Soluble TFRC Off-target Screening | Homolog panel strictly Sequence Verified; distinct theoretical identity by mass spec design. |
| Internalization Rate Quantification | High-purity ECD-Fc supports SPR and cell-based assays; Lentivirus enables stable overexpression lines. |
Live CD71 (TFRC) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD71/TFRC therapeutics is intensifying, with major players shifting focus from conventional monoclonal antibodies toward two dominant engineering paradigms: conditionally activated ADCs for hematologic and solid malignancies, and receptor-mediated transcytosis (RMT) shuttles for CNS delivery. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimal affinity tuning to ensure drugs do not remain trapped in the brain endothelium but successfully undergo transcytosis into the CNS. A critical challenge is minimizing erythroid sink toxicity while maximizing endosomal payload release or blood-brain barrier penetration. Differentiated epitope targeting is key to balancing efficacy and safety.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific BBB Shuttle | Denali, Roche/Genentech, Eli Lilly | Neurodegenerative Diseases (Alzheimer's, Parkinson's, lysosomal storage disorders) | Affinity/Transcytosis Assay (Need high-purity ECD-Fc for SPR and pH-dependent release study) |
| ADC / Probody-Drug Conjugate | CytomX (AbbVie partner), various biopharma | Hematologic Malignancies, Solid Tumors | Internalization Assay (Need Native Glycosylation Antigens and stable lentivirus cell lines) |
| Monoclonal Antibody | Early Stage | Rare Anemias, Iron Overload | Receptor Blocking Assay (Need Sequence Verified Proteins) |
| Radioligand / Diagnostic | Academic and nuclear medicine consortia | Tumor imaging, PK/PD Studies | High-purity labeled antigen for in vitro binding characterization |
Key Mutations and Structural Considerations
CD71/TFRC (UniProt P02786) contains a Protease-Associated (PA) domain critical for its function. Several key mutations are relevant to drug development:
- IMD46 (increased expression): A mutation that elevates both total protein and cell surface expression on T cells, potentially affecting antibody binding and internalization kinetics.
- rs3817672: This variant shows no significant effect on interaction with P. vivax RBP2b but may impact transferrin binding competition; important for off-target screening.
- rs41301381: Documented in dbSNP; its functional impact on receptor conformation or therapeutic engagement should be considered in assay design.
TarMart offers both wild-type and mutant CD71 ECD-Fc proteins to support structure-activity relationship (SAR) studies and to evaluate the effect of these mutations on drug binding.